NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation

NNASDAQ:NMTC
0.75
USD
+0.00
(-0.01%)
-0.88EPS
26.46MMarket Cap
Dec 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.1
0.06
0.65
0.77
1.36
1.12
Basic EPS, GAAP
-0.11
-0.13
-0.22
-0.17
-13.77
- -
-10.29
-15.11
-5.58
-3.75
-3.93
-2.76
-0.54
-0.88
Free Cash Flow per Basic Share
-0.09
-0.09
-0.11
-0.07
-5.99
- -
-8.38
-3.93
-4.86
-2.92
-4.39
-2.5
-0.44
-0.85
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.11
-0.13
-0.29
-0.94
-11.53
-8.19
-1.65
1.68
3.27
3.55
1.57
0.16
0.85
0.43
Tangible Book Value per Share
-0.11
-0.13
-0.29
-1.59
-12.02
-8.57
-1.89
1.55
3.21
3.51
1.54
0.15
0.84
0.43
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
1
1
2
3
3
4
7
8
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
3
9
9
Operating Margin (%)
-2,009.05
-4,646.05
-4,166.44
- -
- -
- -
- -
- -
-5,735.86
-5,860.15
-612.32
-344.26
-46.46
-83.43
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
-5
- -
-7
-14
-10
-10
-12
-12
-4
-7
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-2,446.28
-4,688.75
-8,472.1
- -
- -
- -
- -
- -
-5,584.28
-5,841.95
-607.42
-356.74
-39.63
-78.63
Working Capital
- -
- -
- -
- -
-4
-4
-1
2
6
9
6
2
8
4
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
-5
-4
-1
2
7
10
6
1
7
4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
-230.81
-123.77
-149.61
-348.39
-91.34
-124.66

Capital Structure

USD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
9
9
Market Capitalization
38
40
26

Working Capital

USD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
8
7
6
Cash, Cash Equivalents & STI
4
3
2
Accounts Receivable, Net
3
2
1
Inventories
2
2
2
Total Current Liabilities
1
2
2
Payables & Accruals
1
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
256.94%
180.47%
760.39%
Free Cash Flow
- -
22.93%
-73.78%
Net Income, GAAP
- -
-14.96%
-70.73%
Sales/Revenue/Turnover
- -
- -
163.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
- -
3
2025
3
1
2
3
9
2026
3
2
2
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.84
-0.66
-0.61
-0.67
-2.76
2025
0.35
-0.44
-0.19
-0.19
-0.54
2026
-0.17
-0.28
-0.23
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
David A. Rosa
Full Time Employees
18
Sector
Health technology
Industry
Medical specialties
Address
7599 Anagram Drive Eden Prairie MN United States 55344
IPO Date
Mar 15, 2018
Website
nmtc1.com
Business
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), founded in 2009 and headquartered in Eden Prairie, Minnesota, develops and commercializes minimally invasive, high-definition thin-film electrode technology for diagnostic and therapeutic neurological applications, primarily targeting epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain from failed back surgeries, and other brain-related disorders in the United States. The company's core products include Evo cortical electrodes for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrodes for temporary subsurface brain signal recording, monitoring, and stimulation; and the OneRF radiofrequency ablation system, the world's first FDA-cleared platform for both diagnostic and therapeutic procedures using sEEG electrodes to create lesions in nervous tissue for functional neurosurgery, including trigeminal neuralgia treatment following a recent FDA 510(k) submission. It also pursues applications in spinal cord stimulation, brain stimulation, drug delivery, depression, mood disorders, incontinence, and artificial intelligence-integrated neuromodulation solutions. Recent developments encompass an expanded exclusive distribution agreement with Zimmer Biomet, granting rights to distribute the OneRF system for brain applications with a $3 million upfront payment and potential milestone payments to drive U.S. and international commercialization; a $2.65 million equity financing and $3 million credit facility in 2024 to support operations through mid-2025; filing of a 510(k) submission ahead of schedule for OneRF trigeminal nerve ablation; and appointment of neurosurgeon Dr. Parag Patil as Chief Medical Advisor to advance clinical strategies.

Company News

  • NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System

  • NeuroOne Featured in New York Post on OneRF® Patient's Remarkable Journey to Overcome Debilitating Facial Pain

  • NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program

  • NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Stock Short Interest Climbs 135.8%

  • NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

  • NeuroOne (NASDAQ: NMTC) secures a $4.5M order as revenue climbs again

  • NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

  • Innovative Eyewear (NASDAQ:LUCY) and NeuroOne Medical Technologies (NASDAQ:NMTC) Head-To-Head Review

  • $10 Million in New Markets Tax Credit Financing for a New cold Storage and Refrigerated Logistics Facility in Albertville, AL

  • Analysts Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Price Target at $7.33

  • NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

  • $6 Million in New Markets Tax Credit Financing for the Acquisition, Renovation, and Equipping of a Tractor Assembly Facility in Monroeville, AL

  • NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript

  • NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript

  • Analyzing First Choice Healthcare Solutions (OTCMKTS:FCHS) & NeuroOne Medical Technologies (NASDAQ:NMTC)

  • NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript

  • Brokerages Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) PT at $1.98

  • NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript

  • NeuroOne Medical Technologies (NASDAQ:NMTC) versus Aclarion (NASDAQ:ACON) Head to Head Contrast

  • Contrasting NeuroOne Medical Technologies (NASDAQ:NMTC) and Cannlabs (OTCMKTS:CANL)